Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 8/20 | 0.70 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.62 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.60 |
| ▸ | PPARG | P37231 | 2/20 | 0.60 |
| ▸ | PPARA | Q07869 | 2/20 | 0.60 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | FLT1 | P17948 | 1/20 | 0.57 |
| ▸ | FLT4 | P35916 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7038130 | 0.91 | SERPINE1 (0.70) | ACLYGRIK1SERPINE1PPARGPPARA | |
| SCHEMBL2269604 | 0.89 | ACLY (0.69) | ACLYGRIK1SUCNR1HDAC8HDAC6 | |
| SCHEMBL7040843 | 0.88 | PPARG (0.69) | ACLYSERPINE1PPARGPPARASUCNR1 | |
| SCHEMBL1317521 | 0.88 | ACLY (0.68) | ACLYGRIK1SERPINE1SUCNR1 | |
| SCHEMBL1308769 | 0.87 | PPARG (0.69) | GRIK1PPARGPPARAKDM4ENPSR1 | |
| SCHEMBL1315890 | 0.87 | ACLY (0.67) | ACLYGRIK1SERPINE1SUCNR1 | |
| SCHEMBL2891026 | 0.86 | PPARG (0.68) | GRIK1PPARGPPARASUCNR1KDM4E | |
| SCHEMBL2274998 | 0.85 | ACLY (0.80) | ACLYGRIK1SERPINE1SUCNR1KDM4E | |
| SCHEMBL14075267 | 0.83 | SERPINE1 (0.80) | ACLYGRIK1SERPINE1SUCNR1KDM4E | |
| SCHEMBL2272049 | 0.83 | ACLY (0.78) | ACLYGRIK1SERPINE1SUCNR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | ACLY 653/4885GRIK1 2029/4885SERPINE1 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.